Introduction {#s1}
============

Tissue regeneration is of vital importance for restoring tissue structure and function following damage. Skeletal muscle has a remarkable capacity to self-repair after severe injuries, a process dependent on muscle stem cells (MuSCs) ([@bib54]). MuSCs originate from a PAX3/7+ progenitor cells that in late fetal life acquire their characteristic anatomical position between the basal lamina and the plasma membrane of muscle fibers ([@bib35]; [@bib53]). MuSCs are indispensable for postnatal muscle growth ([@bib69]; [@bib49]), maintenance ([@bib27]; [@bib49]), and regeneration upon injury ([@bib31]; [@bib36]; [@bib43]; [@bib57]). The majority of juvenile MuSCs acquire a non-proliferative, quiescent state around 3 weeks of post-natal life to ensure cellular/genomic integrity and long-term survival ([@bib30]; [@bib69]; [@bib14]). However, once stimulated by homeostatic demand or damage, adult MuSCs exit quiescence, re-enter the cell cycle, and provide differentiated progeny for muscle repair, while a subpopulation self-renews to preserve the quiescent pool ([@bib54]). The myogenic regulatory factors including MYOD and MYOGENIN orchestrate MuSCs commitment and progression through the myogenic lineage ([@bib66]), while the signals that trigger cell cycle exit and (re-) entry into quiescence remain more elusive.

Cell cycle is a tightly synchronized process responding to positive and negative signals, while inappropriate growth arrest can result in cancer, malformations during development, and defective stem cell renewal ([@bib75]; [@bib33]; [@bib58]). Cyclin-dependent kinase inhibitors (CDKIs) are negative cell cycle regulators. CDKIs are divided into two structurally and functionally defined families: the INK4 family (including Cdkn2a, Cdkn2b, Cdkn2c, and Cdkn2d) and the Cip/Kip family (including Cdkn1a, Cdkn1b, and Cdkn1c) ([@bib8]).

Although members of the Cip/Kip family have been shown to inhibit proliferation and promote differentiation in embryonic muscle or in myoblasts in vitro, their involvement in postnatal MuSC cell cycle regulation is less well documented ([@bib24]; [@bib55]; [@bib76]; [@bib38]; [@bib13]; [@bib73]). Given the emerging importance of Cdkn1c in stem cell quiescence ([@bib33]; [@bib78]; [@bib21]), we explored its role in adult myogenesis and MuSC-supported regeneration. Using mouse mutants and ex vivo analysis, we provide evidence that Cdkn1c is involved in the early phase following MuSC activation events, with its genetic ablation leading to impaired muscle regeneration associated with decreased differentiation and increased proliferation. We further show that Cdkn1c is not detected in quiescent MuSCs but is induced upon activation and maintained in differentiating myogenic cells. Finally, we show that Cdkn1c subcellular localization is specifically regulated during adult myogenesis, with a progressive cytoplasmic to nuclear translocation as activated myoblasts proceed to differentiation. Our results suggest that muscle stem cells require Cdkn1c activity for the dynamic control of growth arrest during adult myogenesis.

Results {#s2}
=======

Cdkn1c is required for postnatal myogenesis {#s2-1}
-------------------------------------------

Although *Cdkn1c* loss is generally associated with perinatal death ([@bib70]; [@bib75]; [@bib62]; [@bib32]), a few *Cdkn1c* mutant mice survived in a mixed CD1;B6 background (4.2%; [Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}). *Cdkn1c*-deficient mice displayed reduced body weight compared to control littermates ([Figure 1---figure supplement 1B--C](#fig1s1){ref-type="fig"}). However, there was no significant difference in forelimb grip strength between *Cdkn1c* mutant and control mice at 1 or 2 months of age when the strength was calculated on a per weight basis. Strength was even slightly higher in 3- or 4-month-old *Cdkn1c* mutant mice compared to controls ([Figure 1---figure supplement 1D](#fig1s1){ref-type="fig"}). This difference could be explained by the smaller body weight of *Cdkn1c* mutants, possibly leading to increased relative grip strength (N/kg) in mutants. To evaluate the role of CDKN1c in muscle homeostasis, we examined sections of the hindlimb *Tibialis anterior* (TA) muscles in adult mice. Histological analysis showed that *Cdkn1c* knock-out muscles contained smaller fibers and displayed increased fibrosis ([Figure 1A--D](#fig1){ref-type="fig"}), implying hindered myogenic differentiation. The amount of centrally located nuclei, indicative of ongoing regeneration, was comparable in mutants and controls ([Figure 1E](#fig1){ref-type="fig"}). Myofiber culture conditions used allow MuSCs to become activated, start dividing (T24-48), and eventually, proceed to myogenic differentiation or self-renewal of the quiescent pool (T72) (Zammit et al., 2004). The number of PAX7+ MuSC on freshly isolated myofibers of *Extensor digitorum longus *(EDLs) was increased in *Cdkn1c* mutant mice compared to the controls ([Figure 1F--G](#fig1){ref-type="fig"}). Furthermore, PAX7+ MuSCs on *Cdkn1c* mutant myofibers were mostly MYOD-, at a similar percentage to controls ([Figure 1H](#fig1){ref-type="fig"}), indicating that Cdkn1c is not regulating MuSCs quiescence. When single myofibers were cultured for 72 hr (T72), *Cdkn1c* mutants displayed an increased ratio of PAX7+ MYOD- self-renewing cells and a decreased ratio of PAX7-MYOD+ differentiating myoblasts ([Figure 1I--J](#fig1){ref-type="fig"}). Taken together, our data suggest that in the absence of CDKN1c the MuSC compartment is correctly established, but a proportion of the MuSC population undergo increased self-renewal at the expense of differentiation.

![*Cdkn1c* deficiency impairs normal muscle growth.\
(**A**) Hematoxylin and Eosin (HE) and Sirius red staining of control (Ctrl) and *Cdkn1c* mutant (*Cdkn1c*-Mut) mouse *Tibialis anterior *(TA) muscles were performed to examine muscle histology, centrally located nucleated myofibers, and fibrosis. Scale bars, 100 μm. (**B**) Histogram showing the average of myofiber diameters (μm). (**C**) Histogram of average fibrotic area per TA muscle. (**D**) Fiber size (μm) distribution in control and *Cdkn1c* mutant mice. (**E**) Histogram of number of fibers with centrally located nuclei. (**F**) PAX7+ (green) MuSCs (arrows) on the myofibers isolated from EDL muscles of *Cdkn1c* mutant and control mice. MYOD (red) is not normally expressed in PAX7+ MuSCs at T0 (quiescence). DAPI (blue) shows all nuclei. Scale bars, 50 μm. (**G**) Numbers of PAX7+ satellite cells on the myofibers isolated from EDL. (**H**) Ratio of MYOD+ activated cells per PAX7+ MuSC on the myofibers isolated from EDL muscles of *Cdkn1c* mutant and control mice. (**I**) Immunofluorescence for PAX7 (green) and MYOD (red) at T72 in single myofiber cultures. Arrows and arrowheads show PAX7+MYOD- quiescent satellite cells and PAX7-MYOD+ differentiating cells, respectively. Scale bars, 50 μm. (**J**) Quantification of ratios of PAX7+ and MYOD+ cells per fiber at T72. Nuclei were counter-stained with DAPI. \*p≤0.05, \*\*p≤0.01.](elife-33337-fig1){#fig1}

Next, we evaluated the impact of CDKN1c loss on skeletal muscle regeneration. We performed intramuscular cardiotoxin (CTX) injections into the *Tibialis anterior* (TA) and sacrificed the mice at 3, (d3), 4 (d4), 7 (d7), and thirty (d30) days post-injury, to evaluate early and late time points of the regeneration procedure. Once muscle degeneration is induced, MuSCs undergo: (1) activation, (2) proliferation to expand their population, (3) self-renewal of the quiescent pool for future needs, and (4) differentiation for newly generated fibers and muscle repair ([@bib54]). At d3 post-injury, loss of *Cdkn1c* promoted myoblasts proliferation and counteracted differentiation, as shown by increased EdU+ incorporation and reduced MYOD+EdU+ fraction, respectively. ([Figure 2---figure supplement 1A,B](#fig2s1){ref-type="fig"}). At d4 post-injury, *Cdkn1c*-deficient muscles showed smaller embryonic myosin (eMyHC)+ myofibers, a marker for early myofiber formation, compared to controls ([Figure 2A,C](#fig2){ref-type="fig"}). At d7 post-injury, *Cdkn1c*-deficient muscles showed increased cell infiltration and smaller and heterogeneous myofiber formation ([Figure 2A,B,D](#fig2){ref-type="fig"}), suggesting a delay in the regeneration process. At d30, signs of impaired regeneration associated with smaller fibers were observed ([Figure 2A,B,E](#fig2){ref-type="fig"}), including deposition of fibrotic tissue ([Figure 2A,F](#fig2){ref-type="fig"}) in *Cdkn1c*-mutant mice. Next, we evaluated the MuSC population from isolated myofibers of EDLs at d30 and TA muscle sections. The number of PAX7+ MuSCs was increased in *Cdkn1c* mutants compared to the controls ([Figure 2G--H](#fig2){ref-type="fig"}; [Figure 2---figure supplement 1C,D](#fig2s1){ref-type="fig"}) while the proportion of MYOD+ MuSCs was not altered ([Figure 2I](#fig2){ref-type="fig"}). Therefore, our data suggest that Cdkn1c is required for postnatal muscle repair. In addition, *Cdkn1c* mutant myogenic cells demonstrated increased propensity for stem-cell self-renewal during both tissue establishment and regeneration.

![CDKN1c deficiency delays muscle regeneration.\
(**A**) Embryonic myosin (eMyHC)/LAMININ/DAPI, Hematoxylin and Eosin (HE), and Sirius red staining of twelve- to fifteen-week-old control (Ctrl) and *Cdkn1c* mutant mouse TA muscles were performed for histological and fibrosis characterization 4, 7 or thirty days after cardiotoxin (CTX) injection. Scale bars, 100 μm. (**B**) Fiber size (μm) distribution in control (Ctrl) and *Cdkn1c* mutant (*Cdkn1c*-Mut) mice 7 (upper panel) or thirty (lower panel) days after CTX injection. (**C**) Histogram of average embryonic MyHC+ fiber diameters (μm) 4 days after CTX injection. (**D**) Histogram of average fiber diameters (μm) 7 and thirty days after CTX injection. (**E**) Fiber size (μm) distribution in control and *Cdkn1c* mutant mice thirty days after CTX injection. (**F**) Histogram of average fibrotic area per TA muscle. (**G**) PAX7+ (green) MuSCs (arrows) on the myofibers isolated from EDL muscles of *Cdkn1c* mutant and control mice thirty days after CTX injection. MYOD (red) is occasionally expressed in PAX7+ MuSCs (arrow heads). DAPI (blue) shows all nuclei. Scale bars, 50 μm. (**H**) Numbers of PAX7+ MuSCs on the EDL isolated myofibers . (**I**) Ratio of MYOD+ activated cells per PAX7+ MuSC on the myofibers isolated from EDL muscles of *Cdkn1c* mutant and control mice. Nuclei were counter-stained with DAPI. Scale bars, 100 μm. \*p≤0.05, \*\*p≤0.01.](elife-33337-fig2){#fig2}

CDKN1c regulates the balance between proliferation and differentiation in activated myoblasts {#s2-2}
---------------------------------------------------------------------------------------------

We next abrogated CDKN1c specifically in adult MuSC to avoid cell non-autonomous effects and bypass the impact of CDKN1c loss during development. To conditionally ablate *Cdkn1c*, we have generated a floxed *Cdkn1c* allele (*Cdkn1c^Flox^*) to enable conditional knock-out of *Cdkn1c* using the Cre/loxP system ([@bib32]). Given that *Cdkn1c* is an imprinted gene expressed only by the maternal allele ([@bib34]), we used heterozygotes with maternal inheritance of *Cdkn1c^Flox^*, hereafter indicated as *Cdkn1c^Flox(m)/+^*. To specifically target the MuSCs and their progeny, we intercrossed *Cdkn1c^Flox^* mice with the *Pax7^CreERT2^* line ([@bib30]). In the compound mice, tamoxifen (TMX) administration results in CreERT2 translocation to the nucleus and *Cdkn1c* excision in the MuSC lineage. One week of TMX administration led to 84.5% recombination efficiency ([Figure 3---figure supplement 1A--B](#fig3s1){ref-type="fig"}). We then inserted *Cdkn1c^Flox^* and *Pax7^CreERT2^* in the *ROSA^mTmG^* background ([@bib44]). These double-fluorescent mice report Cre activity by expressing membrane-Tomato (mT) prior to Cre-mediated excision and membrane-GFP (mG) after excision. This allowed us to selectively isolate recombined (GFP+) MuSC cells.

We isolated by flow cytometry GFP+ MuSCs of control (*Pax7^CreERT2^; Cdkn1c^+/+^; ROSA^mTmG/+^*) and *Cdkn1c-*deficient (*Pax7^CreERT2^; Cdkn1c ^Flox(m)/+^; ROSA^mTmG/+^*) mice. Collected cells grew in expansion conditions (20% fetal bovine serum, 10% horse serum) up to 70% confluence and then were serum-deprived to differentiate for 1 or 3 days ([Figure 3A](#fig3){ref-type="fig"}). *Cdkn1c* transcript and protein were induced by differentiation in control cells ([Figure 3B--C](#fig3){ref-type="fig"}). In contrast, they were not detected in cells from mutant animals ([Figure 3B,D](#fig3){ref-type="fig"}), demonstrating efficient Cre-mediated recombination of the *Cdkn1c* allele in FACS-isolated cells. We then performed primary myoblast cultures from control and *Cdkn1c*-deficient mice. We monitored proliferating cells under 'growth' (high serum) or 'differentiation' (low serum) conditions, and at d1 and d3 post-differentiation we stained with early (e.g. MYOGENIN) or late (i.e. Myosin heavy chain, MyHC) differentiation markers, respectively. Consistent with the function of CDKN1cas a cell cycle inhibitor, we observed increased proliferation in primary myoblasts derived from MuSC-specific *Cdkn1c* mutant mice. When cells were maintained in growth conditions for 5 days, we observed 50% and 38% more EdU+ and KI67+ cells, respectively, in the absence of CDKN1c ([Figure 3E--H](#fig3){ref-type="fig"}), suggesting that CDKN1c is involved in restraining cell cycle progression. Slightly more PAX7+ EdU+ cells were observed in the *Cdkn1c*-deficient myoblast cultures, while differences in MYOD+ EdU+ or MYOGENIN+ EdU+ populations did now show significant differences ([Figure 3---figure supplement 1C--F](#fig3s1){ref-type="fig"}). Furthermore, in cultures of FACS-isolated MuSCs from MuSC-specific *Cdkn1c*-deficient mice, myogenic differentiation was impaired. One-day post-differentiation, MYOGENIN was significantly decreased ([Figure 3I,K,L](#fig3){ref-type="fig"}). In addition, myotube formation 3 days post-differentiation was severely compromised ([Figure 3J,M,N](#fig3){ref-type="fig"}). We also detected a similar increase in cell proliferation and reduction in myogenic differentiation in primary myoblasts isolated from global *Cdkn1c* mutant mice ([Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}). In conclusion, both MuSC-specific and global ablation of CDKN1c led to increased primary myoblasts proliferation at the expense of myogenic differentiation. Together, our data demonstrate that CDKN1c is required in MuSCs for correct cell cycle regulation and differentiation during postnatal myogenesis.

![*Cdkn1c* deficiency impairs myogenic differentiation.\
(**A**) Time-course of tamoxifen (TMX) administration, muscle satellite cell harvest (FACS arrow) and culture (light gray bar for growth culture conditions, dark gray bar for differentiation culture conditions). Analyzed animals were *Pax7^CreERT2/+^; Cdkn1c^Flox(m)/+^;Rosa^mTmG^* (*Cdkn1c* cKO) and *Pax7^CreERT2/+^; Cdkn1c^+/+^;Rosa^mTmG^* (control; Ctrl); maternal inheritance of the imprinted *Cdkn1c* is indicated by superscript (m). (**B**) *Cdkn1c* transcript levels of control and *Cdkn1c* cKO myoblast cultures 3 days post-differentiation. ND; not detected. (**C--D**) Control (**C**) and *Cdkn1c* cKO (**D**) myoblast cultures were examined for CDKN1c protein (red) following three days under differentiation conditions. (**E--N**) Control and *Cdkn1c* cKO myoblast cultures were examined for EdU+ (light blue) cells (**E, G, H**), KI67+ cells (**F**), MYOGENIN+ cells (green; **I, K, L**), and myotube formation (**J, M, N**). Nascent myotubes were marked with myosin heavy chain (MyHC; green; **M, N**). Nuclei were counter-stained with DAPI (blue). Graphs show quantification of EdU and KI67 expression under growth conditions (**E, F**), MYOGENIN expression following 24 hr under differentiation conditions (**I**), and MyHC+ cells following 72 hr under differentiation conditions (**J**). Data show mean +SD, n = 3 animals. Asterisks indicate significance; \*p≤0.05, \*\*\*p≤0.001. Scale bars, 40 μm (**C, K**), 1000 μm (**G, M**).](elife-33337-fig3){#fig3}

Satellite-cell-specific CDKN1c loss compromises muscle regeneration {#s2-3}
-------------------------------------------------------------------

We next evaluated the impact of MuSC-specific *Cdkn1c* ablation, driven by *Pax7^CreERT2^* ([@bib30]), on skeletal muscle regeneration after injury. Following 4 weeks of tamoxifen administration to induce recombination in adult (8- to 12-week-old) mice, we injected control and *Pax7^CreERT2/+^; Cdkn1c^Flox^* (*Cdkn1c* cKO) TA muscles with CTX and evaluated muscle repair at 7 days post-injury ([Figure 4A](#fig4){ref-type="fig"}), having achieved 94.5% recombination efficiency in MuSCs ([Figure 4---figure supplement 1A--B](#fig4s1){ref-type="fig"}). Of note, *Pax7^CreERT2/+^* (hereafter, Cre control) animals only express one allele of *Pax7*, as the Cre recombinase is inserted into the *Pax7* gene. Hence, in all experiments we also included Cre control mice, as we found that *Pax7^CreERT2^* ([@bib30]) heterozygous mice display a mild regeneration phenotype ([Figure 4B--G'](#fig4){ref-type="fig"}), hence potentially acting as sensitizing background. Histological analysis at d7 post-injury showed normal tissue repair in wild-type (Wt) muscles ([Figure 4B,C](#fig4){ref-type="fig"}). In contrast, Cre control muscles showed increased cell infiltration and reduced regenerated myofibers of smaller sizes compared to Wt ([Figure 4B'](#fig4){ref-type="fig"}; [Figure 4---figure supplement 1C--D](#fig4s1){ref-type="fig"}), while muscle regeneration was severely compromised in *Cdkn1c* cKO muscles, in which newly formed myofibers were rare and small and most of the tissue consisted of cell infiltration and fat deposits ([Figure 4B'', C''](#fig4){ref-type="fig"}; [Figure 4---figure supplement 1C--D](#fig4s1){ref-type="fig"}). Furthermore, induction of early differentiation was delayed, as evidenced by the presence of embryonic eMyHC+ fibers in *Cdkn1c* cKO and Cre control, but not in Wt muscles at this time point ([Figure 4D--E''](#fig4){ref-type="fig"}). Consistent with the lack of tissue regeneration, we observed a massive diminution of the MuSC compartment in *Cdkn1c* cKO muscles ([Figure 4F--H](#fig4){ref-type="fig"}). Together, our data reveal that CDKN1c expression in the myogenic lineage is required for muscle repair.

![MuSC-specific *Cdkn1c* ablation hinders muscle regeneration.\
(**A**) Time-course of tamoxifen administration, intramuscular injury of TA muscle (CTX arrow), and muscle harvest (D7 arrow). (**B--G**) Cryosections of TA muscle were stained for histological and satellite cell population characterization 7 days after CTX injection. Analyzed animals at (**B-G**) were wild-type littermates (Wt; *Pax7^+^; Cdkn1c^+^*; **B--G**), Cre control (*Pax7^CreERT2^*; **B'--G'**), and *Cdkn1c* cKO (*Pax7^CreERT2^; Cdkn1c^Flox^*; **B''--G''**). (**B**) HE staining for histologic characterization of the muscles. (**C**) Oil Red O staining for evaluation of fat infiltration of the muscles. (**D--E**) embryonic myosin (eMYHC, red)/LAMININ (LAM, green) immunofluorescence to mark newly formed myofibers post-regeneration. (**F--G**) PAX7 (red)/LAMININ (LAM, green) immunofluorescence to mark PAX7+ satellite cells. Nuclei in (**D-G**) were counter-stained with DAPI (blue). Scale bars, 50 μm. (**H**) Quantification of (**F-G**). Data show mean +SD, n ≥ 5 animals. Asterisks indicate significance; \*\*p≤0.01.](elife-33337-fig4){#fig4}

Dynamic CDKN1c expression in adult myogenesis {#s2-4}
---------------------------------------------

To analyze the expression of CDKN1c during MuSC-mediated myogenesis, we isolated single myofibers with their associated PAX7+ MuSCs from EDL muscles of adult wild-type mice. Immunostaining experiments, using a CDKN1c-specific antibody, showed that quiescent MuSCs were not labeled ([Figure 5---figure supplement 1A](#fig5s1){ref-type="fig"}). Similarly, MuSCs of resting adult TA muscles were CDKN1c-negative following labeling of cryosections ([Figure 5---figure supplement 1B](#fig5s1){ref-type="fig"}). To evaluate the kinetics of [[CDKN1c]{.ul}]{.ul} expression during activation, self-renewal, and differentiation, we analyzed myofibers that were cultured from 24 to 72 hr. [@bib74]During the initial proliferation state (T24-T48) MuSCs co-express PAX7 and MYOD ([@bib74]). Activated PAX7+ and MYOD+ myoblasts at T24-T48 presented with increasing amounts of [[CDKN1c]{.ul}]{.ul}. Unexpectedly, this negative cell cycle regulator was not expressed in the quiescent population, but in activated MuSCs entering the cell cycle. However, during this early proliferation phase, [[CDKN1c]{.ul}]{.ul} was restricted to the cytoplasm ([Figures 5A--B](#fig5){ref-type="fig"} and [6A--B](#fig6){ref-type="fig"}). Consistent with these findings, [[CDKN1c]{.ul}]{.ul} was mainly restricted to the cytoplasm at d3 following CTX injection in vivo, a time point when most cells are in a proliferative state ([Figure 5C](#fig5){ref-type="fig"}).

![Cdkn1c cytoplasmic expression after satellite cell activation.\
(**A**) Satellite-cell-derived myoblasts (**T24--T48**) of single EDL myofibers stained with PAX7 (green) and [[CDKN1c]{.ul}]{.ul} (red). Arrowheads indicate PAX7+ cells. (**B**) Satellite cell-derived myoblasts of single EDL myofibers stained with MYOD (green) and [[CDKN1c]{.ul}]{.ul} (red). Arrowheads indicate MYOD+ cells. Nuclei were counter-stained with DAPI. n ≥ 3. Scale bars, 40 μm. (**C**) [[CDKN1c]{.ul}]{.ul} (red) staining of TA muscle at 3 (**D3**) or t (**D13**) days after CTX injection. Asterisks indicate regions with cytoplasmic [[CDKN1c]{.ul}]{.ul}. \# indicates central nuclei of newly formed fibers during muscle regeneration. Nuclei were counter-stained with DAPI. Scale bars, 20 μm.](elife-33337-fig5){#fig5}

![Cdkn1c expression and subcellular localization during satellite cell activation and differentiation.\
(**A--D**) Immunofluorescence for PAX7 (A; green), MYOD (B; green), MYOGENIN (C; green) or KI67 (D; green) and Cdkn1c (red) at T72 in single myofiber cultures of EDL muscles and quantification of PAX7+ (**A**), MYOD+ (**B**), MYOGENIN+ (**C**) or KI67+ (**D**) cells that co-expressed [[CDKN1c]{.ul}]{.ul} over the time-course of the culture. Cytoplasmic (light blue) or nuclear (dark blue) localization of [[CDKN1c]{.ul}]{.ul} is indicated in the graphs. Scale bars, 40 μm. (**E**) Immunofluorescence for Cyant fluorescent protein (CFP, green), KI67 (purple), and [[CDKN1c]{.ul}]{.ul} (red) in transduced (i.e. CFP+) myoblasts at T72 in single myofiber cultures. Fibers were transduced with empty retroviruses (control; left panel), retroviruses expressing full-length *Cdkn1c* (Cdkn1c FL; middle panel) or Nuclear localization signal-deficient *Cdkn1c* (Cdkn1c--NLS; right panel). (**F**) Quantification of transduced (CFP+) myoblasts that were proliferating (KI67+). Nuclei were counter-stained with DAPI (blue). Scale bars, 20 μm. Data show mean +SD, n ≥ 3 animals, 20--32 fibers/animal. \*p≤0.05 compared to control virus.](elife-33337-fig6){#fig6}

At T72, clusters composed of cells at different states are observed, including differentiation (loss of PAX7 expression associated with expression of MYOD and MYOGENIN) and self-renewal (maintenance of PAX7, loss of MYOD, and lack of MYOGENIN) ([@bib74]). Thus, there is a mixed population of self-renewing (cells expressing PAX7 alone), activated/proliferating (cells co-expressing PAX7 and MYOD), and differentiating (cells expressing MYOGENIN and/or MYOD) myogenic cells. At this stage, we observed high percentages of [[CDKN1c]{.ul}]{.ul} expression in each of these populations ([Figure 6A--C](#fig6){ref-type="fig"}). Interestingly, as differentiation proceeded (MYOD+ followed by MYOGENIN +at T72), Cdkn1c expression became increasingly nuclear ([Figure 6B--C](#fig6){ref-type="fig"}). Although Cdkn1c was mostly cytoplasmic in PAX7+/Cdkn1c + T72 myoblasts, Cdkn1c exhibited nuclear presence in around 25% of MYOD+/Cdkn1c+ and 55% of MYOGENIN+/Cdkn1c + T72 myoblasts ([Figure 6A--C](#fig6){ref-type="fig"}). In line with this, Cdkn1c protein was mainly restricted to cell nuclei at late stages of regeneration following in vivo muscle injury (d13 post-CTX; [Figure 5C](#fig5){ref-type="fig"}). Finally, similarly to the T24-T48 activated/cycling populations of myoblasts in single myofibers ex vivo, Cdkn1c continued to be present in KI67+ proliferating cells at T72, yet limited to their cytoplasm ([Figure 6D](#fig6){ref-type="fig"}). Next, to evaluate whether Cdkn1c nuclear translocation was linked with its association with MYOD ([@bib56]; [@bib64]; [@bib17]; [@bib46]; [@bib9]; [@bib5]; [@bib73]), we used data generated by a MYOD ChIP sequencing experiment ([@bib11]) to identify MYOD-binding sites at muscle regulatory regions. We performed ChIP experiments with an anti-Cdkn1c antibody to test whether Cdkn1c shares these binding sites with MYOD, and we found no significant enrichment at any of the tested sites ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}).

Finally, to establish whether the subcellular localization of [[CDKN1c]{.ul}]{.ul} directly affects the cycling status of myoblasts, we generated retroviruses encoding full-length *Cdkn1c* (Cdkn1c FL) or *Cdkn1c* lacking the Nuclear localization signal (Cdkn1c --NLS), using Cyan fluorescence protein (CFP) as a reporter to identify transduced cells ([Figure 6E](#fig6){ref-type="fig"}). A mock CFP retrovirus was used as control ([Figure 6E--F](#fig6){ref-type="fig"}). Overexpression of Cdkn1c FL in single myofiber cultures was associated with nuclear [[CDKN1c]{.ul}]{.ul} protein ([Figure 6E](#fig6){ref-type="fig"}) and a marked decrease in cycling myoblasts ([Figure 6E,F](#fig6){ref-type="fig"}). In contrast, forced expression of the NLS-deficient construct restricted [[CDKN1c]{.ul}]{.ul} to the cytoplasm ([Figure 6E](#fig6){ref-type="fig"}) and did not induce cell cycle exit as Cdkn1c FL ([Figure 6E,F](#fig6){ref-type="fig"}). By contrast, overexpression of either Cdkn1c FL or Cdkn1c --NLS did not alter the proportions of cells entering myogenic differentiation, as evidenced by MYOD and/or MYOGENIN expression ([Figure 6---figure supplement 2A--D](#fig6s2){ref-type="fig"}). Lastly, in order to eliminate potential interference with endogenous Cdkn1c[[CDKN1c]{.ul}]{.ul} in these experiments, we repeated them in *Cdkn1c-*deficient myoblasts following FACS isolation ([Figure 6---figure supplement 2E](#fig6s2){ref-type="fig"}). Comparably to the ex vivo system of single myofibers ([Figure 6E](#fig6){ref-type="fig"}, [Figure 6---figure supplement 2A--D](#fig6s2){ref-type="fig"}), we observed cell cycle exit, uncoupled from myogenic differentiation, in Cdkn1c FL but not Cdkn1c --NLS ([Figure 6---figure supplement 2E--G](#fig6s2){ref-type="fig"}). Together, these results show that nuclear [[CDKN1c]{.ul}]{.ul} promotes growth arrest, while cytoplasmic localization of the protein - observed at early stages of MuSC activation - is compatible with proliferation. Furthermore, our data suggest uncoupling of cell cycle exit and myogenic differentiation.

Discussion {#s3}
==========

Regenerative adult myogenesis is crucial for recovery from injuries, but can be compromised by degenerative or disease states that affect the functional capacity of skeletal muscle stem cells (MuSC). The maintenance of MuSC function largely depends on the entry and maintenance of a non-cycling, reversible quiescent state. The molecular mechanisms that control MuSC cell cycle transitions and adult myogenesis have gained significant interest in recent years, as a way to understand post-trauma tissue restoration and, subsequently, to design efficient innovative therapies when it is defective.

Focusing on cell cycle exit signals and given our recent findings on the role of [[CDKN1c]{.ul}]{.ul} in cell fate decisions in embryonic/fetal myogenesis ([@bib73]), we hypothesized that [[CDKN1c]{.ul}]{.ul} may control cell cycle and differentiation of MuSCs in adult muscle. Indeed, *Cdkn1c* deficiency compromised muscle regeneration following in vivo injury ([Figure 2A--D](#fig2){ref-type="fig"}; [Figure 4](#fig4){ref-type="fig"}) and hindered primary myoblast differentiation and myotube formation ([Figure 3](#fig3){ref-type="fig"}; [Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}). [[CDKN1c]{.ul}]{.ul} expression correlates with differentiation in many other cell types ([@bib68]), while in myogenic cultures [[CDKN1c]{.ul}]{.ul} has also been considered as a differentiation marker ([@bib55]; [@bib41]). Nevertheless, the consequences of its ablation on adult muscle have not been examined previously, notably because of the perinatal lethality of *Cdkn1c* mutant mice. Maintaining the mice in a mixed CD1;B6 background allowed us to obtain some survivors, while analyzing floxed *Cdkn1c* mice allowed cell-specific studies. In vivo and in vitro analysis of both models demonstrated that lack of *Cdkn1c* compromised myogenic differentiation (*[Figures 1](#fig1){ref-type="fig"}--[4](#fig4){ref-type="fig"}, [Figure 3---figure supplement 2](#fig3s2){ref-type="fig"})*. In the case of *Cdkn1c*-null mice, there was increased MuSC self-renewal at the expense of differentiation ([Figures 1](#fig1){ref-type="fig"}--[2](#fig2){ref-type="fig"}), while conditional deletion of *Cdkn1c* in adult mice diminished the MuSC compartment after injury ([Figure 4](#fig4){ref-type="fig"}). These seemingly contradictory results might depend on compensatory mechanisms that are activated when *Cdnk1c* deletion is induced prenatally (mutant) versus postnatally (cKO). Moreover, in our cKO mice, compounding effects of inactivating both *Pax7* (due to CreERT2 insertion in the PAX7 locus) and *Cdkn1c* cannot be excluded. However, comparing the *Cdkn1c* cKO mice to the Cre control, showed a much more severe regeneration impairment in the former ([Figure 4](#fig4){ref-type="fig"}). Together, our data on *Cdkn1c* mutant and cKO mice implicate an important function for [[CDKN1c]{.ul}]{.ul} in adult myogenesis, similarly to its emerging importance in the quiescence and renewal of several other stem cell types \[Matsumoto et a., 2011; [@bib72]; [@bib21]).

Examining the myoblast populations expressing [[CDKN1c]{.ul}]{.ul} (i.e. quiescent vs. activated), we did not detect [[CDKN1c]{.ul}]{.ul} in quiescent MuSCs on sections or isolated myofibers of resting adult (8--12 weeks) muscle ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). On the contrary, [[CDKN1c]{.ul}]{.ul} was readily detected in interstitial cells ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). Our finding is consistent with previous reports of high [[CDKN1c]{.ul}]{.ul} levels in adult muscle ([@bib34]; [@bib47]) and lack of [[CDKN1c]{.ul}]{.ul} in FACS-isolated postnatal MuSC populations ([@bib13]) or myofiber-associated MuSCs ([@bib45]). In contrast, an early study detected [[CDKN1c]{.ul}]{.ul} in quiescent MuSCs ([@bib20]) which were isolated with a FACS protocol using an antibody previously described by the same group ([@bib19]). However, this antibody immuno-reacts with bone marrow cells ([@bib19]), while [[CDKN1c]{.ul}]{.ul} has a well-established role and presence in the hematopoietic lineage ([@bib33]; [@bib78]). Furthermore, [[CDKN1c]{.ul}]{.ul} immunostaining in [@bib20] was performed with an antibody against the [[CDKN1c]{.ul}]{.ul} carboxy-terminus, which might cross-react with the respective domain of [[CDKN1b]{.ul}]{.ul} ([@bib34]; [@bib22]; [@bib48]). Combining our observation with previous reports ([@bib19]; [@bib20]; [@bib13]; [@bib45]); present study\], we conclude that quiescent MuSCs do not express [[CDKN1c]{.ul}]{.ul}. Instead, it is established that they express [[CDKN1b]{.ul}]{.ul}, another member of the CDKI family including [[CDKN1c]{.ul}]{.ul} ([@bib13]); our unpublished data\].

Upon MuSC activation and differentiation, we show that [[CDKN1c]{.ul}]{.ul} is strongly upregulated ([Figures 5](#fig5){ref-type="fig"}--[6](#fig6){ref-type="fig"}). Accordingly, activation of MuSCs during muscle regeneration has been shown to induce [[CDKN1c]{.ul}]{.ul}, with its levels peaking at d3-4 ([@bib71]); our unpublished observations\]. The early induction of [[CDKN1c]{.ul}]{.ul} upon activation might be associated with MYOD expression, a transcription factor with which [[CDKN1c]{.ul}]{.ul} has been implicated in a positive feedback loop ([@bib56]; [@bib46]). Specifically, MYOD has been shown to induce *Cdkn1c* both by disrupting a chromatin loop to release the *Cdkn1c* promoter and by upregulating intermediate factors ([@bib64]; [@bib17]; [@bib9]; [@bib5]). Furthermore, we previously identified a muscle-specific *Cdkn1c* regulatory element that MYOD binds and transactivates ([@bib73]), while co-immunoprecipitation assays revealed direct [[CDKN1c]{.ul}]{.ul}-MYOD binding ([@bib56]). Moreover, *MyoD* mutant mice present a similar muscle phenotype as our *Cdkn1c*-deficient mice ([@bib37]), also consistent with *Cdkn1c* being a direct downstream gene of MYOD, and possible association of MYOD and [[CDKN1c]{.ul}]{.ul}. MYOD is expressed within hours after MuSC activation ([@bib74]; [@bib77]) and sustains the transition from quiescence to cell cycle via the replication-related factor CDC6 ([@bib77]). MYOD induces growth arrest in non-myogenic cell lines ([@bib16]; [@bib61]) and has a well-established role for entry into the myogenic lineage. While the possibility of [[CDKN1c]{.ul}]{.ul} associating with MYOD to regulate [[CDKN1c]{.ul}]{.ul} translocation was an attractive hypothesis, [[CDKN1c]{.ul}]{.ul} was not found associated with MYOD binding in muscle-specific gene regulatory regions ([@bib11]) evaluated by ChIP ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}). Remarkably, despite robust expression of MYOD, myoblasts continue to proliferate and do not proceed to differentiation for several days ([@bib63]). In fact, in dividing myoblasts MYOD activity is inhibited by Id proteins and CDK/Cyclin complexes ([@bib67]). Furthermore, additional factors, including MYOGENIN, were suggested to initiate or enhance transcription of some MYOD targets ([@bib7]; [@bib10]).

We demonstrate robust [[CDKN1c]{.ul}]{.ul} presence in activated MuSCs, including expression in proliferating myoblasts in isolated myofiber cultures (e.g. KI67+ cells at T72, cycling cells at T24-T48; [Figures 5](#fig5){ref-type="fig"}--[6](#fig6){ref-type="fig"}). These observations might contradict its traditional function as cell cycle exit factor ([@bib29]; [@bib34]) and its role in growth arrest during embryonic myogenesis ([@bib76]; [@bib73]). Our data, however, suggest that the uncoupling of [[CDKN1c]{.ul}]{.ul} growth arrest activity in proliferating myoblasts of isolated myofiber cultures is related to its subcellular localization. [[CDKN1c]{.ul}]{.ul} is cytoplasmically restricted in activated myoblasts but is progressively detected in the nucleus as differentiation takes place ([Figure 6](#fig6){ref-type="fig"}). Indeed, forced [[CDKN1c]{.ul}]{.ul} expression in myoblasts of isolated myofiber cultures led to nuclear [[CDKN1c]{.ul}]{.ul} and growth arrest, while overexpression of Nuclear localization signal-deficient [[CDKN1c]{.ul}]{.ul} was compatible with myoblast proliferation ([Figure 6](#fig6){ref-type="fig"}; [Figure 6---figure supplement 2](#fig6s2){ref-type="fig"}). On the contrary, [[CDKN1c]{.ul}]{.ul} cyto-nuclear shuttling was not related to myogenic differentiation, suggesting an uncoupling of cell cycle exit and myogenic differentiation ([Figure 6---figure supplement 2](#fig6s2){ref-type="fig"}), in line with our previous observations in embryonic muscles ([@bib73]).

We have not identified the molecular events underlying the [[CDKN1c]{.ul}]{.ul} nucleo-cytoplasmic shuttling, although some observations might explain this pattern. Firstly, [[CDKN1c]{.ul}]{.ul} could be implicated in cell cycle progression through CDK/Cyclin assembly, similarly to its Cip/Kip siblings ([@bib39]; [@bib25]; [@bib28]; [@bib52]). In the absence of [[CDKN1a]{.ul}]{.ul} and [[CDKN1b]{.ul}]{.ul}, [[CDKN1c]{.ul}]{.ul} is solely responsible for CDK/Cyclin complex stabilization in mouse embryonic fibroblasts ([@bib12]). However, this might be less likely in myoblasts, where Cdkn1c-MYOD binding engages the [[CDKN1c]{.ul}]{.ul} helix domain ([@bib56]) that was found indispensable for CDK/Cyclin binding and inhibition ([@bib26]; [@bib56]). Moreover, in agreement with [[CDKN1c]{.ul}]{.ul} function as a cell cycle inhibitor, we observed reduced differentiation and increased proliferation in its absence ([Figures 1I--J](#fig1){ref-type="fig"}, [2A--E](#fig2){ref-type="fig"} and [3E--N](#fig3){ref-type="fig"}). Secondly, [[CDKN1c]{.ul}]{.ul} could be involved in nucleo-cytoplasmic distribution of cyclins or CDKs, as previously observed in other cell types. [[CDKN1c]{.ul}]{.ul} has been shown to interfere with the nuclear translocation of cyclin D1 ([@bib78]) and to relocalize a fraction of CDK2 into the cytoplasm ([@bib18]). Thirdly, while in the cytoplasm, [[CDKN1c]{.ul}]{.ul} might participate in MuSC mobilization, one of the earliest manifestations of their activation ([@bib60]). Cytoplasmic [[CDKN1c]{.ul}]{.ul} was described to regulate cell motility together with LIM-kinase1 ([@bib65]; [@bib15]; [@bib23]). Although we did not detect LIM-kinase1 in myogenic cells, we cannot exclude association with other, yet uncharacterized, partners. Future studies are expected to elucidate the roles of [[CDKN1c]{.ul}]{.ul} in different sub-cellular compartments of myoblasts.

In conclusion, our data indicate that [[CDKN1c]{.ul}]{.ul} plays essential roles at the initial phase following MuSC activation. We suggest that [[CDKN1c]{.ul}]{.ul} acts at that early phase, as a) in vivo, *Cdkn1c* mutants display a strong phenotype during the first days after injury and b) *Cdkn1c* mutant myoblasts have compromised functions in cultures that last a few days, thus resembling the first events after MuSC activation. [[CDKN1c]{.ul}]{.ul} presence is compatible with activation/proliferation and possibly represents an early activation event. Its loss profoundly affects ex vivo myogenic differentiation and delays in vivo post-injury recovery, which may lead to increased MuSC self-renewal. Therefore, the reduced regeneration capacity of *Cdkn1c*-mutant muscle is not caused by decreased numbers of MuSCs, but results from the reduction of myogenic differentiation, which increases propensity for stem-cell self-renewal. Defective stem cell cycle dynamics and continuous activation/proliferation can lead to DNA damage accumulation, apoptosis, pool exhaustion, and inability to support homeostatic or regenerative demands. A better understanding of cell cycle regulation in MuSCs is imperative to define the molecular events underlying their long-term preservation.

Materials and methods {#s4}
=====================

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type (species)\       Designation                  Source or reference                               Identifiers                                                              Additional information
  or resource                                                                                                                                                                           
  ----------------------------- ---------------------------- ------------------------------------------------- ------------------------------------------------------------------------ -------------------------------------------------------------------------------------------------------
  Strain, strain background\    *Cdkn1c^tm1Sje^*             The Jackson Laboratory;\                          MGI: J40203,\                                                            
  (*M. musculus*)                                            PMID: 9144284                                     RRID:[IMSR_JAX:003336](https://scicrunch.org/resolver/IMSR_JAX:003336)   

  Strain, strain background\    *p57^flox^*                  PMID: 28196404                                                                                                             Mouse line generated by the\
  (*M. musculus*)                                                                                                                                                                       group of F.Relaix and\
                                                                                                                                                                                        characterized in\
                                                                                                                                                                                        [@bib32];\
                                                                                                                                                                                        Genesis 55(4) doi:\
                                                                                                                                                                                        10.1002/dvg.23025

  Strain, strain background\    *Pax7^CreERT2/+^*            The Jackson Laboratory;\                          MGI: J:150962;\                                                          Mouse line obtained\
  (*M. musculus*)                                            PMID: 19554048                                    RRID:[IMSR_JAX:012476](https://scicrunch.org/resolver/IMSR_JAX:012476)   from C.M. Fan

  Strain, strain background\    *Rosa^mTmG^*                 The Jackson Laboratory;\                          MGI: J:124702;\                                                          
  (*M. musculus*)                                            PMID: 17868096                                    RRID:[IMSR_JAX:007576](https://scicrunch.org/resolver/IMSR_JAX:007576)   

  Genetic reagent (synthetic)   *pGEMT-Easy* vector          Promega                                           A1360                                                                    

  Cell line (*Homo sapiens*)    293T                         DSMZ                                              ACC635;\                                                                 <https://www.dsmz.de/catalogues/details/culture/ACC-635.html?tx_dsmzresources_pi5%5BreturnPid%5D=192>
                                                                                                               RRID:[CVCL_0063](https://scicrunch.org/resolver/CVCL_0063)               

  Cell line (*M. musculus*)     C2C12                        American Type Culture\                            CRL-1772;\                                                               Cell line maintained\
                                                             Collection (ATCC);\                               RRID: [CVCL_0188](https://scicrunch.org/resolver/CVCL_0188)              in E. Gomes lab
                                                             PMID: 28966089                                                                                                             

  Antibody                      anti-CD31-PE (monoclonal)    eBiosciences                                      12-0311-81;\                                                             
                                                                                                               RRID:[AB_465631](https://scicrunch.org/resolver/AB_465631)               

  Antibody                      anti-CD45-PE (monoclonal)    eBiosciences                                      12-0451-81;\                                                             
                                                                                                               RRID:[AB_465667](https://scicrunch.org/resolver/AB_465667)               

  Antibody                      anti-embryonic MyHC\         DSHB                                              F1.652;\                                                                 
                                (mouse monoclonal)                                                             RRID:[AB_528358](https://scicrunch.org/resolver/AB_528358)               

  Antibody                      anti-embryonic MyHC\         Santa Cruz                                        sc53091;\                                                                
                                (mouse monoclonal)                                                             RRID:[AB_670121](https://scicrunch.org/resolver/AB_670121)               

  Antibody                      anti-GFP (chicken\           Abcam                                             ab13970;\                                                                
                                polyclonal)                                                                    RRID:[AB_300798](https://scicrunch.org/resolver/AB_300798)               

  Antibody                      anti-integrin a-biotin\      Miltenyi Biotec                                   130-101-979;\                                                            
                                (mouse)                                                                        RRID:[AB_2652472](https://scicrunch.org/resolver/AB_2652472)             

  Antibody                      anti-IgG (rabbit)            Diagenode                                         C15410206                                                                

  Antibody                      anti-KI67 (mouse\            BD Pharmingen                                     556003;\                                                                 
                                monoclonal)                                                                    RRID:[AB_396287](https://scicrunch.org/resolver/AB_396287)               

  Antibody                      anti-Laminin (rabbit\        Sigma-Aldrich                                     L9393;\                                                                  
                                polyclonal)                                                                    RRID:[AB_477163](https://scicrunch.org/resolver/AB_477163)               

  Antibody                      anti-Laminin (rat\           Sigma-Aldrich                                     4H8-2;\                                                                  
                                monoclonal)                                                                    RRID:[AB_784266](https://scicrunch.org/resolver/AB_784266)               

  Antibody                      anti-Laminin (rabbit\        Novus Biological                                  NB300-144AF647                                                           
                                polyclonal)                                                                                                                                             

  Antibody                      anti-MyHC (mouse\            DSHB                                              mf20-c;\                                                                 
                                monoclonal)                                                                    RRID:[AB_2147781](https://scicrunch.org/resolver/AB_2147781)             

  Antibody                      anti-MyoD (mouse\            DAKO                                              M3512;\                                                                  
                                monoclonal)                                                                    RRID:[AB_2148874](https://scicrunch.org/resolver/AB_2148874)             

  Antibody                      anti-MyoD (rabbit\           Santa Cruz                                        sc-760;\                                                                 
                                polyclonal)                                                                    RRID:[AB_2148870](https://scicrunch.org/resolver/AB_2148870)             

  Antibody                      anti-Myogenin\               DSHB                                              F5D;\                                                                    
                                (mouse monoclonal)                                                             RRID:[AB_2146602](https://scicrunch.org/resolver/AB_2146602)             

  Antibody                      anti-p57 (goat polyclonal)   Santa Cruz                                        sc1039;\                                                                 
                                                                                                               RRID:[AB_2078158](https://scicrunch.org/resolver/AB_2078158)             

  Antibody                      anti-p57 (mouse\             Santa Cruz                                        sc56431;\                                                                
                                monoclonal)                                                                    RRID:[AB_2298043](https://scicrunch.org/resolver/AB_2298043)             

  Antibody                      anti-p57 (rabbit\            Santa Cruz                                        sc8298;\                                                                 
                                polyclonal)                                                                    RRID:[AB_2078155](https://scicrunch.org/resolver/AB_2078155)             

  Antibody                      anti-Pax7 (mouse\            DSHB                                              PAX7-c;\                                                                 
                                monoclonal)                                                                    RRID:[AB_528428](https://scicrunch.org/resolver/AB_528428)               

  Antibody                      anti-Sca-1-PE (mouse)        eBiosciences                                      12-5981-81;\                                                             
                                                                                                               RRID:[AB_466085](https://scicrunch.org/resolver/AB_466085)               

  Antibody                      fab fragment affinity-\      Jackson ImmunoResearch                            115-007-003                                                              
                                purified antibody (goat)                                                                                                                                

  Sequence-based reagent        AGGGCATATCC\                 Eurogentec                                        N/A                                                                      qPCR HPRT (Forward primer)
                                AACAACAAACTT                                                                                                                                            

  Sequence-based reagent        GTTAAGCAGTA\                 Eurogentec                                        N/A                                                                      qPCR HPRT (Reverse primer)
                                CAGCCCCAAA                                                                                                                                              

  Sequence-based reagent        CTGAAGGACCA\                 Eurogentec                                        N/A                                                                      qPCR p57 (Forward primer)
                                GCCTCTCTC                                                                                                                                               

  Sequence-based reagent        AAGAAGTCGTT\                 Eurogentec                                        N/A                                                                      qPCR p57 (Reverse primer)
                                CGCATTGGC                                                                                                                                               

  Sequence-based reagent        ATCTGAGGTCA\                 Eurogentec                                        N/A                                                                      ChIP qPCR Mef2a\
                                GCCATTTGGT                                                                                                                                              (Forward primer)

  Sequence-based reagent        GCTAAGGACAG\                 Eurogentec                                        N/A                                                                      ChIP qPCR Mef2a\
                                CTGTGACCTG                                                                                                                                              (Reverse primer)

  Sequence-based reagent        TTAAAGACATGTG\               Eurogentec                                        N/A                                                                      ChIP qPCR Lmn2b\
                                GCAACAGACTAC                                                                                                                                            (Forward primer)

  Sequence-based reagent        TGCTCTTTCTGTA\               Eurogentec                                        N/A                                                                      ChIP qPCR Lmn2b\
                                CTGTGTGGTG                                                                                                                                              (Reverse primer)

  Sequence-based reagent        GGAGTGATTGA\                 Eurogentec                                        N/A                                                                      ChIP qPCR Lincmd1\
                                GGTGGACAGA                                                                                                                                              (Forward primer)

  Sequence-based reagent        CTCTCCCACCTG\                Eurogentec                                        N/A                                                                      ChIP qPCR Lincmd1\
                                TTTGTGTCTT                                                                                                                                              (Reverse primer)

  Sequence-based reagent        AATTACAGCCG\                 Eurogentec                                        N/A                                                                      ChIP qPCR Myogenin\
                                ACGGCCTCC                                                                                                                                               (Forward primer)

  Sequence-based reagent        CCAACGCCACA\                 Eurogentec                                        N/A                                                                      ChIP qPCR Myogenin\
                                GAAACCTGA                                                                                                                                               (Reverse primer)

  Sequence-based reagent        CAGCTCCTTG\                  Eurogentec                                        N/A                                                                      ChIP qPCR Desmin-proximal\
                                CCCTGTGAAA                                                                                                                                              (Forward primer)

  Sequence-based reagent        TGTAGCCCTCC\                 Eurogentec                                        N/A                                                                      ChIP qPCR Desmin proximal\
                                TGACATCAC                                                                                                                                               (Reverse primer)

  Sequence-based reagent        CCAAAAGGG\                   Eurogentec                                        N/A                                                                      ChIP qPCR Desmin distal\
                                CCGATGAGGAA                                                                                                                                             (Forward primer)

  Sequence-based reagent        TAGAGACAGA\                  Eurogentec                                        N/A                                                                      ChIP qPCR Desmin distal\
                                CCAGTGGCGG                                                                                                                                              (Reverse primer)

  Commercial assay or kit       LightCycler 480 SYBR\        Roche-Sigma-Aldrich                               04887352001                                                              
                                Green I Master                                                                                                                                          

  Commercial assay or kit       iDeal ChIP-seq kit           Diagenode                                         C01010051                                                                

  Commercial assay or kit       RNasy Micro Kit              QIAGEN                                            74004                                                                    

  Commercial assay or kit       Transcriptor First Strand\   Roche-Sigma-Aldrich                               4379012001                                                               
                                cDNA Synthesis Kit                                                                                                                                      

  Chemical compound, drug       bFGF                         Peprotech                                         450--33                                                                  20 ng/ml

  Chemical compound, drug       bFGF                         Thermo Fisher Scientific                          PHG0263                                                                  20 ng/ml

  Chemical compound, drug       Bovine serum\                Jackson ImmunoResearch                            10001620                                                                 0.2%
                                albumin (BSA)                                                                                                                                           

  Chemical compound, drug       Cardiotoxin                  Latoxan                                           L8102                                                                    10 µM

  Chemical compound, drug       Cardiotoxin                  Sigma-Aldrich                                     217503--1 mg                                                             10 µM

  Chemical compound, drug       Chicken embryo extract       MP-Biomedical                                     92850145                                                                 0.5%

  Chemical compound, drug       Chicken embryo extract       Seralab                                           CE-650-J                                                                 1%

  Chemical compound, drug       collagen                     BD Biosciences                                    354236                                                                   culture dish coating

  Chemical compound, drug       Collagenase type I           Sigma-Aldrich                                     C0130                                                                    0.2%

  Chemical compound, drug       Collagenase type I           Worthington Biochemical Corp                      9001-12-1                                                                

  Chemical compound, drug       Collagenase A                Roche-Sigma-Aldrich                               11088793001                                                              0.2% w/v

  Chemical compound, drug       DAPI (4',6-diamidino-2-\     Thermo Fisher Scientific                          D1306                                                                    
                                phenylindole\                                                                                                                                           
                                dihydrochloride)                                                                                                                                        

  Chemical compound, drug       Dispase II                   Roche-Sigma-Aldrich                               4942078001                                                               2.4 U/ml

  Chemical compound, drug       DNaseI                       Roche-Sigma-Aldrich                               11284932001                                                              10 ng/mL

  Chemical compound, drug       Dulbecco's Modified\         Thermo Fisher Scientific                          41966                                                                    single myofiber culture
                                Eagle's Medium (DMEM)                                                                                                                                   

  Chemical compound, drug       DMEM with GlutaMAX           Thermo Fisher Scientific                          61965                                                                    myoblast culture

  Chemical compound, drug       EdU                          Thermo Fisher Scientific                          C10340                                                                   2 μM

  Chemical compound, drug       F-10 Ham\'s media            Sigma-Aldrich                                     N6635                                                                    N/A

  Chemical compound, drug       Fetal bovine serum (FBS)     Thermo Fisher Scientific                          10270                                                                    20%

  Chemical compound, drug       Fetal calf serum (FCS)       Eurobio                                           CVFSVF00-01                                                              10% (prol/tion medium),\
                                                                                                                                                                                        2% (diff/tion medium)

  Chemical compound, drug       Fluoromount-G                Southern Biotech                                  0100--01                                                                 

  Chemical compound, drug       Hanks\' Balanced\            Thermo Fisher Scientific                          14025                                                                    
                                Salt Solution (HBSS)                                                                                                                                    

  Chemical compound, drug       Hepes                        Thermo Fisher Scientific                          15630                                                                    0.1M

  Chemical compound, drug       Horse serum                  Thermo Fisher Scientific                          26050088                                                                 5% (coating), 10% (culture)

  Chemical compound, drug       L-glutamine                  Thermo Fisher Scientific                          25030                                                                    20 mM

  Chemical compound, drug       matrigel                     Corning Life Sciences                             354230                                                                   1:20 in DMEM

  Chemical compound, drug       Penicillin/streptomycin      Life Technologies                                 15140                                                                    1X

  Chemical compound, drug       Pyruvate                     Thermo Fisher Scientific                          11360                                                                    10 mM

  Software, algorithm           Photoshop CS5                <https://www.adobe.com/products/photoshop.html>   RRID:[SCR_014199](https://scicrunch.org/resolver/SCR_014199)             

  Other (anti-biotin beads)     anti-biotin beads            Miltenyi Biotec                                   130-090-485;\                                                            MACS
                                                                                                               RRID:[AB_244365](https://scicrunch.org/resolver/AB_244365)               

  Other (anti-PE beads)         anti-PE beads                Miltenyi Biotec                                   130-048-801;\                                                            MACS
                                                                                                               RRID:[AB_244373](https://scicrunch.org/resolver/AB_244373)               

  Other (chamber slides)        chamber slide                Nalge Nunc International                          177445                                                                   myoblast culture

  Other (culture plates)        petri dish                   Sigma-Aldrich                                     Z692301                                                                  single myofiber culture

  Other (LD column)             LD column                    Miltenyi Biotec                                   130-042-901                                                              MACS

  Other (MS column)             MS column                    Miltenyi Biotec                                   130-042-201                                                              MACS

  Other (grip strength meter)   grip strength meter          Columbus Instruments                              1027CSM-D54                                                              
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Mouse lines {#s4-1}
-----------

The following mouse lines have been previously described: *Pax7^CreERT2/+^* ([@bib30]), *Rosa^mTmG^* (The Jackson Laboratory, stock 007576), *Cdkn1c*^cKO\ (m)/+^ (*Cdkn1c* is imprinted with preferential expression of the maternal allele; superscript (m) indicates maternal inheritance) ([@bib32]), *Cdkn1c*^+/-^ ([@bib75]). *Cdkn1c*^+/-^female mice (C57BL/B6J background, Jackson Laboratory) were bred with CD1 (Evigo) male mice to generate *Cdkn1c^m/-^* CD1/B6 hybrid mice. Non-mutant littermates were used as controls. For recombination induction with the *Pax7^CreERT2^* allele, mice were fed in tamoxifen diet (TD.55125.I, Envigo). C57BL/6J (Janvier) mice were used as wild-type animals for [Figures 5](#fig5){ref-type="fig"}--[6](#fig6){ref-type="fig"}. Adult mice of 8 to 16 weeks of age were used. At least three mice per genotype were assessed. All animals were maintained inside a barrier facility, and all in vivo experiments were performed in accordance with the French and European Community guidelines (File No: 15--018 from the Ethical Committee of Anses/ENVA/UPEC) and Institutional Animal Care and the Use Committee of University of Minnesota (1604-33660A) for the care and use of laboratory animals.

Single myofiber isolation and culture {#s4-2}
-------------------------------------

Single muscle fibers were isolated by enzymatic digestion and mechanical disruption of *EDL* muscles ([@bib42]). For enzymatic digestion, muscles were incubated for 90 min at 37°C with 0.2% collagenase type I (C0130, Sigma-Aldrich) in Penicillin/Streptomycin(P/S)-supplemented DMEM (41966, ThermoFisher Scientific). For mechanical disruption, muscles were transferred to 5%-horse-serum-coated deep petri dishes (Z692301, Sigma-Aldrich) with P/S-supplemented DMEM and medium was flushed against the muscle. Detached fibers were transferred into new dishes with P/S-supplemented DMEM. For timed culture, all fibers were transferred after finishing isolation into 5%-horse-serum-coated six-well plates and cultured in the presence of 10% horse serum and 0.5% chicken embryo extract (\#092850145, MP Biomedicals). Single myofibers for [Figure 6E--F](#fig6){ref-type="fig"} and [Figure 6---figure supplement 2](#fig6s2){ref-type="fig"} were cultured in the presence of 20% FBS (\#10270, Life Technologies) and 1% chicken embryo extract (\#CE-650-J, Seralab).

Retroviral cloning and infection {#s4-3}
--------------------------------

Cdkn1c cDNA was cloned by PCR from mouse cDNA and subcloned in the *pGEMT-Easy* vector (\#A1360, Promega). An additional primer was also designed to produce Cdkn1c cDNA lacking the NLS and following sequences ([@bib29]). Full-length or -NLS Cdkn1c were subsequently subcloned -using XhoI and EcoRI added to cloning primers- into the MISSINCK retroviral production vector, which was based on the *pMSCV- IRES-eGFP* (MIG) vector ([@bib51]), substituting eGFP with an insulin signal sequence-Cyan Fluorescent Protein (CFP)-KDEL sequence in order to restrict fluorescent tracker expression to the endoplasmic reticulum and Golgi ([@bib2]). MISSINCK retroviruses expressing either full-length or -NLS Cdkn1c were produced in 293T (DSMZ, \#ACC635) cells, and retroviral supernatant was acquired 50 hr post-transfection of 293 T cells. For transduction, single myofiber cultures were incubated with 1:10 diluted retroviral supernatant from 24 to 72 hr after fiber isolation ([Figure 6E](#fig6){ref-type="fig"}; [Figure 6---figure supplement 2A--D](#fig6s2){ref-type="fig"}) and primary myoblasts were incubated with 1:10 diluted retroviral supernatant from 48 to 120 hr after FACS isolation ([Figure 6---figure supplement 2E--G](#fig6s2){ref-type="fig"}).

Cell sorting and culture {#s4-4}
------------------------

Using the tamoxifen-inducible Cre line *Pax7^CreERT2^*, membrane-GFP is expressed in muscle satellite cells (MuSCs) of *Pax7^CreERT2^; Rosa^mTmG^* mice. Hindlimb muscles were dissociated by 0.2% w/v collagenase A (11088793001, Roche) and 2.4 U/ml dispase II (04942078001, Roche) in digestion buffer \[HBSS (14025, Thermo Scientific), 1% Penicillin/Streptomycin, 10 ng/ml DNase I (11284932001, Sigma), 0.4 mM CaCl~2~, 5 mM MgCl~2~, 0.2% bovine serum albumin (BSA; 0010001620, Jackson ImmunoResearch)\] with 90 min incubation at 37°C. Dissociated muscles were filtered through 100 μm and 40 μm cell strainers. GFP +cells were collected based on gating of GFP signal.

Sorted cells were plated on matrigel (354230, Corning Life Sciences)-coated chamber slides (177445, Nalge Nunc International). They were initially cultured in high-serum conditions (referred to as 'growth phase') with 20% fetal bovine serum, 10% horse serum and 1:4000 bFGF (20 ng/ml; 450-33B, PeproTech) in DMEM + Glutamax (61965, ThermoFisher Scientific) supplemented with 1% P/S, 20 mM L-glutamine (25030, Thermo Scientific), 10 mM pyruvate (11360, Thermo Scientific), and 0.1M Hepes (15630, Thermo Scientific). Upon reaching 70% confluence at 5 days post-plating, they were switched to low-serum conditions (5% horse serum in P/S-supplemented DMEM + Glutamax) to differentiate (referred to as 'differentiation phase'). EdU (2 μM; C10340, Thermo Fisher Scientific) chase was performed for 2 hr. EdU-incorporating cells were detected according to the manufacturer's protocol.

Myoblast culture {#s4-5}
----------------

Hindlimb muscle of control or *Cdkn1c* mutant mice was harvested for isolation of MuSC-derived primary myoblasts as described previously ([@bib3]; [@bib40]). Briefly, muscle was dissected, minced and then digested in type I collagenase (Worthington Biochemical Corp.). The dissociated cells were filtered, and incubated with *anti*-CD45-PE, *anti*-Sca-1-PE, and *anti*-CD31-PE antibodies (all from eBiosciences) and integrin α-biotin antibody (Miltenyi Biotec) followed by anti-PE beads (Miltenyi Biotec). For magnetic-activated cell sorting (MACS), LD column (Miltenyi Biotec) was used for negative selection to remove non-muscle cells. Flow-through fraction was used for incubation with anti-biotin beads (Miltenyi Biotec) followed by MS column (Miltenyi Biotec). Enriched MuSCs were fractionated as a positive fraction. MuSC-derived primary myoblasts were cultured in growth media, F-10 Ham\'s media supplemented with 20% FBS, 20 ng/ml basic fibroblast growth factor (Invitrogen) and 1% penicillin-streptomycin (Gibco) on culture dishes coated with collagen (BD Biosciences), and the growth medium was changed every two days. Procedures for EdU experiments and myogenic differentiation were described above.

Gene expression analysis {#s4-6}
------------------------

RNA was extracted with the RNeasy Micro kit (74004, Qiagen), according to the manufacturer's instructions. cDNA was synthetized with the Transcriptor First Strand cDNA Synthesis kit (04379012001, Roche). RT-qPCR reactions were carried out in triplicate using the LightCycler 480 SyBR Green I Master (04887352001, Roche). Hypoxanthine Phosphoribosyltransferase 1 (HPRT) transcripts were used for normalization. Oligonucleotides sequences were AGGGCATATCCAACAACAAACTT and GTTAAGCAGTACAGCCCCAAA for *HPRT* and CTGAAGGACCAGCCTCTCTC and AAGAAGTCGTTCGCATTGGC for *Cdkn1c*.

C2C12 culture and ChIP-qPCR {#s4-7}
---------------------------

C2C12 (PMID: 28966089) cells were grown in DMEM High Glucose (\#41966, Life Technologies) supplemented with 10% SVF (Eurobio) until reaching 70% confluence and then they were changed to low serum (2% SVF), differentiation, conditions for four days. Cells were collected and processed for ChIP with the iDeal ChIP-seq kit (C01010051, Diagenode) according to manufacturer's instructions. 1 μg of a mouse anti-Cdkn1c (sc56341, Santa Cruz) or IgG negative control (C15410206, Diagenode) was used. The precipitated and input chromatins were analyzed by qPCR. Primer sequences are listed in [Table 1](#table1){ref-type="table"}.
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###### Sequences of primers used for the ChIP-qPCR.

  Regulated gene/region   Forward primer              Reverse primer
  ----------------------- --------------------------- -------------------------
  *Mef2a*                 ATCTGAGGTCAGCCATTTGGT       GCTAAGGACAGCTGTGACCTG
  *Lmn2b*                 TTAAAGACATGTGGCAACAGACTAC   TGCTCTTTCTGTACTGTGTGGTG
  *Lincmd1*               GGAGTGATTGAGGTGGACAGA       CTCTCCCACCTGTTTGTGTCTT
  *Myogenin*              AATTACAGCCGACGGCCTCC        CCAACGCCACAGAAACCTGA
  *Desmin* (proximal)     CAGCTCCTTGCCCTGTGAAA        TGTAGCCCTCCTGACATCAC
  *Desmin* (distal)       CCAAAAGGGCCGATGAGGAA        TAGAGACAGACCAGTGGCGG

Muscle regeneration {#s4-8}
-------------------

Adult (12- to 15-week-old) mice in [Figure 2](#fig2){ref-type="fig"} and [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"} were intramuscularly injected with 70 µl of 10 μM cardiotoxin (CTX) solution (Sigma-Aldrich) into the *Tibialis Anterior* (TA) after being anesthetized by i.p. injection of Avertin (Sigma-Aldrich) ([@bib4]). Muscles were recovered 3, 4, 7 or 30 days post-injury. Five mg/kg of EdU was injected at 24 hr before sacrifice for EdU staining.

Adult (8- to 12-week old) mice in [Figure 4](#fig4){ref-type="fig"} and [Figure 5C](#fig5){ref-type="fig"} were intramuscularly injected with 45 ul of 10 μM CTX (Latoxan) into the TA after being anesthetized by i.p. injection of ketamine-xylasin. Muscles were recovered at 3, 7 or 13 days post-injury.

Grip strength test {#s4-9}
------------------

The maximum grip strength using a *grip strength* meter (Columbus Instruments) was determined by taking the average of the three highest values out of the 15 values collected and normalized by body weight ([@bib1]). We performed three sets of five consecutive measurements for one set, and mice were allowed to rest for at least 20 min between the sets.

Immunohistochemistry {#s4-10}
--------------------

Sections: Muscles were frozen fresh in liquid nitrogen-cooled isopentane and sectioned at 8 µm. Frozen sections were fixed with 4% paraformaldehyde/PBS for 20 min at room temperature. For hematoxylin-eosin staining, nuclei were stained with hematoxylin (Sigma-Aldrich) for 11 min and cytoplasmes were counter-stained with eosin (Sigma-Aldrich) for 30 s. The sections were then dehydrated with brief passages through increasing concentrations of ethanol (30%, 50%, 70%, 85%, 95%, 100%). Sirius red staining (Sigma-Aldrich) was performed for detection of fibrosis as described previously ([@bib59]). For two-color immunofluorescence, frozen sections were permeabilized with 0.2% Triton X (Sigma-Aldrich) and blocked with M.O.M kit (Vector laboratories) followed by 2% bovine serum albumin (Sigma-Aldrich) at room temperature. For three-color immunofluorescence, sections were permeabilized and blocked with 3% BSA, 10% lamb serum, 0.25% TritonX-100/PBS for 30 min at room temperature. In both cases, immunolabeling was performed at 4°C overnight for primary antibodies and at room temperature for 1 hr for secondary antibodies. To outline fibers with Alexa-conjugated anti-laminin, incubation was performed for 3 hr at room temperature, after washing out the secondary antibody. Nuclei were counterstained blue with DAPI. When mouse-raised antibodies were applied, endogenous mouse IgG was blocked by incubation with goat anti-mouse fab fragment affinity-purified antibody (115-007-003, Jackson Immunoresearch) for 30 min at room temperature.

Single myofibers: After isolation (T0) or following culture (T24, T48, T72), myofibers were fixed with 37°C-preheated 4% paraformaldehyde/PBS for 10 min at room temperature. Fixed fibers were permeabilized with 0.5% TritonX-100/PBS for 8 min, blocked with 10% goat serum, 10% swine serum in 0.025% Tween20/PBS for 45 min and incubated with primary antibody (overnight at 4°C) and secondary antibody (1 hr at room temperature). Nuclei were counterstained blue with DAPI.

Primary myoblast culture: Cell cultures were fixed with 4% paraformaldehyde/PBS for 15 min at room temperature, permeabilized with 0.5% TritonX-100/PBS for 5 min, blocked with 5% BSA, 10% goat serum and immunolabeled with primary antibody (overnight at 4°C) and secondary antibody (1 hr at room temperature). Nuclei were counterstained blue with DAPI.

Antibodies {#s4-11}
----------

The following antibodies were used: chicken anti-GFP 1:1000 (\#ab13970, Abcam), mouse anti-KI67 1:80 (\#556003, BD Pharmingen), mouse anti-MYOD 1:80 (M3512, DAKO), rabbit anti-MYOD 1:1000 (sc304, Santa Cruz), mouse anti-MYOGENIN 1:100 (F5D-c, DSHB), mouse anti-embryonic MyHC 1:50 (F1.652, DSHB), mouse anti-embryonic MyHC 1:300 (sc53091, Santa Cruz), mouse anti-MyHC 1:100 (mf20-c, DSHB), rabbit AlexaFluor647-conjugated anti-laminin 1:200 (NB300-144AF647, Novus Biological), rabbit anti-laminin 1:400 (L9393, Sigma Aldrich), rat anti-laminin 1:1000 (4H8-2, Sigma-Aldrich), mouse anti-PAX7 1:100 (Pax7-c, DSHB), rabbit anti-[[CDKN1c]{.ul}]{.ul} 1:100 (sc8298, Santa Cruz), goat anti-[[CDKN1c]{.ul}]{.ul} 1:50 (sc1039, Santa Cruz), AlexaFluor-coupled secondary antibodies (Life Technologies, Jackson ImmunoResearch).

Graphic editing {#s4-12}
---------------

Graphs and representative photos were arranged in Figure format with the graphics editor Photoshop CS5. Curves were adjusted in some photos with identical adjustments between control and experimental samples. Color intensities of hematoxylin-eosin photos were adjusted to acquire uniform result among different sections.

Statistical test {#s4-13}
----------------

Data of control and mutant mice were compared with the Mann-Whitney U-test, using a significance level of 0.05.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Cellular localization of the cell cycle inhibitor p57kip2 controls proliferation and growth arrest of adult skeletal muscle stem cells\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by Didier Stainier as the Senior Editor. The reviewers have opted to remain anonymous.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this letter to draw your attention to significant concerns that you would need to address before this work could be considered for publication.

Summary:

This manuscript describes a role for the cell-cycle inhibitor p57 in adult skeletal muscle stem cells (MuSCs). Previous work by the same authors indicated that p57 deletion during embryonic development leads to defects in muscle progenitors\' proliferation and differentiation. Similarly, a role for p57 in the proliferation and differentiation of the myogenic C2C12 cell line has been reported.

Here, the authors report that a very small percentage (4.2%) of germline p57 mice survived to adulthood in a mixed background. The surviving animals displayed reduced body weight, decreased myofiber cross-sectional area and increased fibrosis. A marginal increase (1%) of Pax7+ MuSCs was observed on freshly isolated fibers of p57 knock-out mice. Such small increase in Pax7+ MuSCs persisted 30 days after muscle injury. At this time point, no statistically significant difference was noted in Pax7+/MyoD+ committed muscle progenitors of p57 knock-out versus control. To circumvent the lethality observed in germline p57 knock-out mice, the authors selectively deleted p57 in MuSCs by crossing maternal p57fl(m)/+ with tamoxifen-inducible Pax7-CreERT2 mice. Unfortunately, p57 was not efficiently ablated at high frequency. FACS-isolated p57-deleted MuSCs had increased proliferation and decreased differentiation potentials. Quiescent MuSCS did not express p57 which was detected in activated in MuSCs.

Subcellular localization of p57 progressively shifted from the cytoplasm during activation to the nucleus upon differentiation. Overexpression of full-length p57, but not of a mutant incapable of nuclear localization, negatively regulates cell proliferation.

Essential revisions:

1\) Beside causing perinatal lethality, germline p57 ablation induces gross developmental defects owing to its role in controlling quiescence of hematopoietic and neural stem cells. Thus, the combination of very few (\~4%) p57 knock-out surviving animals and the extensive non-cell specific function of p57 make the results of the presented experiments difficult to interpret.

2\) To circumvent the limitations related to germline deletion, the authors have attempted to specifically delete p57 in MuSCs using the Pax7-CreERT2 driver. This approach has been proven unsuccessful in ablating p57 with high frequency. This is a technical issue that should be rectified. Without deleting p57 in the majority of MuSCs, in vivo experiments aimed at evaluating the role of p57 in homeostatic as well as regenerative conditions are simply not possible and the major tenet of this study, i.e., the function of p57 in adult MuSCs, cannot be conclusively determined.

3\) Because of the low recombination of the p57 allele, in vitro experiments were presumably conducted with rare recombined MuSCs. Were there a selection process, the results may be difficult to interpret.

4\) Based on the results presented in Figure 2, the authors conclude that p57 counteracts self-renewal. It remains unclear whether Pax7+ p57-null MuSCs proliferate or return to quiescence 30 days after injury. For this, it is necessary to evaluate cell proliferation by EdU labeling in vivo at later stages after tissue repair (30 days), as well as to determine cell anatomical position and expression of quiescent genes.

5\) The cytoplasmic-nuclear shuttling of p57 should be documented upon MuScs in vivo activation. P57 subcellular localization could be determined in activated MuSCs on cultured myofibers with analysis of p57 protein localization upon in vivo activation. Analysis could be done on muscle stem cells at different early time points after tissue injury, either in tissues or on fixed cells after FACS isolation.

6\) The fate of cells in which p57 has been overexpressed should be investigated to determine whether they are differentiating (Myogenin staining). Moreover, p57 overexpression experiments should be conducted in p57-null MuSCs.

7\) No mechanistic insight of how p57 regulate different function in the cytoplasm and the nucleus is offered. P57 has been reported to associate with MyoD. Does nuclear p57 colocalize with MyoD at muscle regulatory regions? Even data that helps to exclude certain mechanisms would be useful in determining the subcellular functional role of p57.

We are also including the full reviews below in case the additional comments are helpful.

Reviewer \#1:

The authors of this manuscript report that the cyclin-dependent kinase inhibitor p57 regulates skeletal muscle cell differentiation. Constitutive as well as conditional p57 knock-outs display increased proliferating muscle stem cells (MuSCs) and decreased differentiating muscle cells following muscle injury and regeneration. P57 was not expressed in quiescent MuSCs and activated in MuSCs entering the cell cycle. During cell differentiation p57 relocated from the cytoplasmic compartment to the nucleus where it is required to induce growth arrest.

Overall, the experiments are well conducted and the conclusions supported by the results.

While p57 has not been previously ablated in adult muscle cells, there have been several independent reports indicating that p57 either along with p21 or on its own regulates skeletal muscle cell proliferation and differentiation (Zhang et al., 1999; Naito et al., 2016).

Suggestions:

1\) *Pax7^CreERT2^*; p57+/-; *ROSA^mTmG/+^* mice should be challenged with muscle injury and MuSC-mediated repair investigated.

2\) The nuclear role of p57 in promoting growth arrest should be experimentally addressed.

P57 has been reported to associate with MyoD (Reynaud et al., 1999). The authors could evaluate whether p57 is recruited on selected MyoD targets in differentiating myocytes.

Reviewer \#2:

In the manuscript entitled \'Cellular localization of the cell cycle inhibitor p57kip2 controls proliferation and growth arrest of adult skeletal muscle stem cells\' the authors are investigating the role of the cell cycle inhibitor p57kip2 during adult skeletal myogenesis for the first time. p57kip2 has been previously studied as a regulator of stem cell quiescence in other stem cell system such as HSC and neural stem cells (Matsumoto et al., 2011; Zou et al., 2011;Furutachi et al., 2013). Previous work in myogenesis has shown that p57kip2 inhibits proliferation and controls muscle differentiation in embryonic muscle or in myoblasts cell line (C2C12) in vitro.

The manuscript by Mademtzoglou et al., attempts to demonstrate for the first time a role for p57kip2 during proliferation and differentiation of adult skeletal muscle satellite cells (MuSC). In particular, the authors showed that p57kip2 protein is not expressed in quiescent muscle SCs, but its expression is increased upon MuSC activation and retained during differentiation. By using genetic mouse model and ex vivo experiments they showed that p57kip2 is required for proper myogenic lineage progression. Genetic ablation of p57kip2 lead to increased proliferation and self-renew, but muscle differentiation is impaired. Interestingly, they showed that p57kip2 subcellular localization is progressively shifting from cytoplasm during activation to nuclear translocation upon differentiation.

There are two main issues with this manuscript:

1A) The authors revealed a role for p57kip2 during post-natal muscle growth and adult skeletal muscle regeneration relying on the germline p57kip2 mutant mice. However, compensatory upregulation of other cell cycle inhibitors from the Cip/Kip family (p18, p27), as shown previously in HSC (Zou et al., 2011), may diminish the effect of p57 in MuSC. An inducible knockout may give a more profound phenotype than that observed in straight KO mice, as suggested from severe MuSC differentiation defect derived from *Pax7^CreERT2^;p57^flox^* mice (Figure 3J-L) compared to more modest reduced differentiation from p57 mutant myoblasts, shown in Figure 3---figure supplement 1C. In addition, any proliferative phenotype during embryogenesis may negatively impact the adult SC in a regenerative context.

1B) In an attempt to use inducible mutant mice, the authors make a cursory comment that they were not able to achieve high efficiency recombination. This is a technical problem that should be rectified. The analysis of myogenic cell fate should include staining for Pax7, Ki67 and MyoD, at different time points after regeneration (d4, d7 and d30). These additional immunostains would further strengthen the conclusion that loss of p57 results in expansion of progenitors and increased self-renew at expense of differentiation.

1C) in vitro experiments were performed with rare recombined cells, this may be problematic if there is a selection process. Due to these potential artefacts, it is important the authors perform the above experiment.

2A) Despite their attempt to demonstrate that subcellular localization of p57kip2 directly affects the cycling status of myoblasts, they did not fully characterize the molecular mechanisms underlying p57kip2\'s cytoplasm-nuclear shuttling.

In particular, the authors failed to 1) Demonstrate the cellular phenotype of p57kip2 localization specifically in Pax7+ MuSCs and their progeny; 2) Fully understand the mechanism behind p57kip2 cytoplasm-nuclear shuttling and cell cycle/myogenic state.

2B) The authors generated retroviruses encoding the full length p57 (p57FL) or p57 lacking the nuclear localization signal (p57NLS). They showed that overexpression of p57-FL correlates with nuclear localization of the p57 protein and growth arrest based on the absence of Ki67 staining. NO phenotype with P57 lacking NLS. The authors should assess what is the fate of the arrested cells by immunostaining. Are they differentiating (Myogenin)?

In this experimental design, the authors exploit an overexpression system. The authors should perform retrovirus studies in the null background. Finally, can the authors use P57NLS to drive nuclear expression only?

2C) The manuscript lacks mechanistic detail of how P57 functions in a spatially- dependent manner. The authors speculate in the discussion to four potential mechanisms. It is important that some attempt is made to provide the readers with some mechanistic insight-even data that helps to exclude certain mechanisms that may be more tractable, would support the functional role of P57 localization.

Reviewer \#3:

The present work by Mademtzoglou et al. investigates the role of the cell cycle inhibitor p57 on muscle stem cell function. The authors have previously reported that p57 deletion during embryonic development leads to defects in muscle progenitors\' cell fate decisions. Here they extend these findings to adult muscle stem cells by showing that in a mixed background a small percentage of p57 knockout mice survived to adulthood and exhibited reduced body weight and myofiber cross-sectional area and increased fibrosis. These mice also exhibited a slight increase in muscle stem cell number, which on myofibers ex vivo or 30 days after tissue injury in vivo are more biased towards self-renewal at the expenses of myogenic commitment. They complement these studies by conditionally inducing p57 deletion in adult muscle stem cells, and upon isolation and culture they observed consistent results. They report that p57 is initially localized in the cytoplasm during early activation of muscle stem cells, and its progressive nuclear localization correlates with growth arrest and myogenic differentiation. Finally, overexpression of a full length, but not a mutant p57 lacking its nuclear localization signal, has a negative effect on myoblast proliferation. They conclude that p57 does not regulate muscle stem cell quiescence but rather their self-renewal vs. commitment cell fate choices.

Overall, the findings in this well written manuscript are interesting and novel, particularly the subcellular localization of p57 in muscle stem cells, although they could be strengthened by increasing the depth of the mechanism underlying the regulation of this process. Also, additional experiments are required in order to fully support the authors\' interpretation.

1\) Increased self-renewal or failure to reentry into quiescence: In Figure 2 the authors show that p57 knockout mice exhibit a mild increase in the number of muscle stem cells 30 days after injury, but no effect on MyoD expression. The authors conclude that p57 counteracts self-renewal. Are these cells proliferating or they efficiently went back to quiescence? Considering this gene has been previously implicated in stem cell quiescence, it might play a role here in promoting the reentry to this state after tissue repair, even if it is not required for the developmental entry in quiescence. The authors should control for proliferation by EdU labeling in vivo at later stage after tissue repair (30 days), as well as their anatomical location and expression of quiescent genes. In addition, analysis of muscle stem cells should be performed not only at 30 days but also at earlier stages after tissue injury, by immunostaining for Pax7, MyoD and EdU in vivo, in order to evaluate the dynamics of activation and commitment in the native tissue. This would strengthen the interpretation of the findings.

2\) Efficiency of p57 floxing in muscle stem cells: The efficiency of the floxing in Figure 3 should be indicated, in order to evaluate whether the FACS isolation of labeled cells yields sufficient numbers to be representative of the stem cell pool, or a very low percentage that may hold an intrinsic bias in population heterogeneity. This should be discussed in the text.

3\) Validating p57 expression dynamics upon in vivo activation: Data could be strengthened by reinforcing the observation of p57 subcellular localization in activated muscle stem cells on cultured myofibers, with analysis of p57 protein localization upon in vivo activation, i.e. analysis could be done on muscle stem cells at different early time points after tissue injury, either in tissues or immediately fixed after FACS isolation.

4\) Effect of p57 loss on myogenic commitment: In Figure 5 the authors show that overexpression of a full length, but not a mutant p57 lacking its nuclear localization signal, has a negative effect on myoblast proliferation. It would be interesting to test whether there is a similar effect also on myogenic commitment.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

Thank you for resubmitting your work entitled \"Cellular localization of the cell cycle inhibitor Cdkn1c controls growth arrest of adult skeletal muscle stem cells\" for further consideration at *eLife*. Your revised article has been favorably evaluated by Didier Stainier (Senior Editor), and a Reviewing Editor and the original reviewers, one of whom is a member of our Board of Reviewing Editors.

The manuscript has been improved but there are some remaining issues that need to be addressed before acceptance, as outlined below:

The authors have satisfactorily addressed most reviewers\' comments and as a result the revised manuscript is substantially strengthened. There are some remaining concerns, detailed here below, that the authors should address.

1\) Figure 3. Cdkn1c expression is abolished in \~ 100% of the Cdkn1c KO myoblast cultures (Figure 3B-D) and all the subsequent experiments reported in Figure 3 were conducted with these cultures. However, the myoblasts appear to be derived from MuSCs FACS-selected for Cdkn1c deletion. The authors should report the overall deletion efficiency (percentage of Cdkn1c-deleted MuSCs in *Pax7^CreERT2^; Cdkn1c^Flox^*), as this information is relevant to the interpretation of subsequent experiments.

2\) New Figure 4. The authors have chosen to employ a *Pax7^CreERT2^* strain expressing only one Pax7 allele. As such, *Pax7^CreERT2^* mice have reduced Pax7 cells and display increased cell infiltration and reduced regenerating myofibers upon muscle injury. Further regeneration worsening in *Pax7^CreERT2^; Cdkn1c^Flox^* is thus to be ascribed to the compounding effect of inactivating both Pax7 and Cdkn1c, with Pax7 inactivation being the major contributor of reduced Pax7+cells (Figure 4H).

3\) New Figure 4. It is possible that the number of MuSCs is not decreased but rather Pax7 at the level of the gene-protein is decreased. It is important to quantify MuSCs number using a different antibody (syn-4, or m-cadherin). The answer to this question would help to determine the severity of the Pax7 haplo-insufficiency phenotype. In addition, the images representing the figure need to be accompanied by quantification, for instance, the number and size of regenerating fibers across the 3 groups.

4\) New Figure 4. The observed reduced number of Pax7+ cells should also be discussed in more detail, as in most of the other assays the authors show that deletion of Cdkn1c leads to increased self-renewal and impaired myogenic differentiation. It would be useful if the authors could comment on this phenotypic difference in the different conditions. A more thorough analysis of the in vivo phenotype may resolve these contradictions.

10.7554/eLife.33337.021

Author response

> Essential revisions:
>
> 1\) Beside causing perinatal lethality, germline p57 ablation induces gross developmental defects owing to its role in controlling quiescence of hematopoietic and neural stem cells. Thus, the combination of very few (\~4%) p57 knock-out surviving animals and the extensive non-cell specific function of p57 make the results of the presented experiments difficult to interpret.

In the revised manuscript, we added data on satellite-cell-specific p57 deletion in adult MuSCs, using the tamoxifen-inducible Pax7-CreERT2 recombinase. These data are presented in (new) Figure 4. Inclusion of this figure changed the numbering of subsequent figures and figure supplements.

> 2\) To circumvent the limitations related to germline deletion, the authors have attempted to specifically delete p57 in MuSCs using the Pax7-CreERT2 driver. This approach has been proven unsuccessful in ablating p57 with high frequency. This is a technical issue that should be rectified. Without deleting p57 in the majority of MuSCs, in vivo experiments aimed at evaluating the role of p57 in homeostatic as well as regenerative conditions are simply not possible and the major tenet of this study, i.e., the function of p57 in adult MuSCs, cannot be conclusively determined.

In order to provide more conclusive evidence of p57 function in adult MuSCs, we treated *Pax7^CreERT2^; p57^flox^* animals with tamoxifen diet for a total of five weeks. This approach allowed the ablation of p57 in adult muscle satellite cells and their post-regeneration progeny, in contrast to our previous approaches of 3-5 i.p. tamoxifen injections or 1-2 weeks of tamoxifen diet. Ablation of p57 in MuSC led to impaired muscle repair after injury. We also provide relevant controls. The new data are included in new Figure 4.

*3) Because of the low recombination of the p57 allele,* in vitro *experiments were presumably conducted with rare recombined MuSCs. Were there a selection process, the results may be difficult to interpret.*

We agree with the reviewers remark and in the revised manuscript, we strengthened these in vitroresults by in vivoanalysis of MuSC-specific *p57* ablation (in *Pax7^CreERT2^; p57^flox^* animals) during muscle repair (Figure 4). Under these conditions, recombined and non-recombined cells were equally challenged by cardiotoxin-induced muscle degeneration and regeneration and showed a severely compromised potential to reconstitute normal muscle tissue.

Of note, we conducted all in vitroexperiments with freshly isolated 70-80% (recombined) MuSCs, avoiding passages that potentially increase the presumed selection process.

> 4\) Based on the results presented in Figure 2, the authors conclude that p57 counteracts self-renewal. It remains unclear whether Pax7+ p57-null MuSCs proliferate or return to quiescence 30 days after injury. For this, it is necessary to evaluate cell proliferation by EdU labeling in vivo at later stages after tissue repair (30 days), as well as to determine cell anatomical position and expression of quiescent genes.

In our new data shown in Figure 2---figure supplement 1D, PAX7+ *p57*-null MuSCs located underneath the LAMININ+ basal lamina returned to quiescent state 30 days after injury confirmed by EdU staining.

> 5\) The cytoplasmic-nuclear shuttling of p57 should be documented upon MuScs in vivo activation. P57 subcellular localization could be determined in activated MuSCs on cultured myofibers with analysis of p57 protein localization upon in vivo activation. Analysis could be done on muscle stem cells at different early time points after tissue injury, either in tissues or on fixed cells after FACS isolation.

We performed muscle injury and monitored p57 subcellular presence at early and late time points following regeneration in muscle sections. We observed cytoplasmic p57 at D3 post-injury, while later on p57 was present in the central nuclei of the newly-formed, regenerated myofibers. We present data on D3 and D13 postinjury in updated Figure 5.

> 6\) The fate of cells in which p57 has been overexpressed should be investigated to determine whether they are differentiating (Myogenin staining). Moreover, p57 overexpression experiments should be conducted in p57-null MuSCs.

In the revised manuscript we analyzed the effects of p57 overexpression on differentiation, by quantifying the Myogenin+ cells at early and late time points of Myogenin expression in single myofiber culture. Due to the lack of significant difference, we further investigated whether p57 overexpression acts earlier during myogenic differentiation, by analyzing the MyoD+ cells after 72h of single myofiber culture. At that time point, MyoD labels not only activated myoblasts but also those that will proceed to differentiation. Furthermore, we performed overexpression experiments in p57-deficient MuSCs after FACS isolation as requested. These data are now shown in new Figure 6---figure supplement 2.

> 7\) No mechanistic insight of how p57 regulate different function in the cytoplasm and the nucleus is offered. P57 has been reported to associate with MyoD. Does nuclear p57 colocalize with MyoD at muscle regulatory regions? Even data that helps to exclude certain mechanisms would be useful in determining the subcellular functional role of p57.

We thank the reviewers for this comment. To gain insight into the molecular mechanisms of p57 action, we used data generated by a MyoD ChIP sequencing experiment (Cao et al., 2010) to identify MyoD binding sites at muscle regulatory regions. We then performed ChIP experiments with an anti-p57 antibody to test whether p57 shares these binding sites with MyoD. The results are shown in new Figure 6---figure supplement 1.

> Cao Y, Yao Z, Sarkar D, Lawrence M, Sanchez GJ, Parker MH, MacQuarrie KL, Davison J, Morgan MT, Ruzzo WL, Gentleman RC, Tapscott SJ. (2010). Genome-wide MyoD binding in skeletal muscle cells: a potential for broad cellular reprogramming. Dev Cell 18 (4): 662-674.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

> The manuscript has been improved but there are some remaining issues that need to be addressed before acceptance, as outlined below:
>
> The authors have satisfactorily addressed most reviewers\' comments and as a result the revised manuscript is substantially strengthened. There are some remaining concerns, detailed here below, that the authors should address.
>
> 1\) Figure 3. Cdkn1c expression is abolished in \~ 100% of the Cdkn1c KO myoblast cultures (Figure 3B-D) and all the subsequent experiments reported in Figure 3 were conducted with these cultures. However, the myoblasts appear to be derived from MuSCs FACS-selected for Cdkn1c deletion. The authors should report the overall deletion efficiency (percentage of Cdkn1c-deleted MuSCs in Pax7^CreERT2^; Cdkn1c^Flox^), as this information is relevant to the interpretation of subsequent experiments.

We added data on the recombination efficiency in Figure 3---figure supplement 1. The lack of Cdkn1c expression in quiescent MuSCs prevented us from evaluating the percentage of *Cdkn1c*‐deleted MuSCs in *Pax7^CreERT2^;Cdkn1c^Flox^* mice. Instead, we used *Pax7^CreERT2^;Rosa^mTmG^* mice, which express GFP as a result of recombination, and we found that one-week of tamoxifen administration leads to 84.5% recombination (percentage of Pax7+GFP+ cells among Pax7+ satellite cells).

Furthermore, we quantified the recombination efficiency for the experiments presented in Figure 4 and added these data in Figure 4---figure supplement 1 of the revised manuscript.

> 2\) New Figure 4. The authors have chosen to employ a Pax7^CreERT2^ strain expressing only one Pax7 allele. As such, Pax7^CreERT2^ mice have reduced Pax7 cells and display increased cell infiltration and reduced regenerating myofibers upon muscle injury. Further regeneration worsening in Pax7^CreERT2^; Cdkn1c^Flox^ is thus to be ascribed to the compounding effect of inactivating both Pax7 and Cdkn1c, with Pax7 inactivation being the major contributor of reduced Pax7+cells (Figure 4H).

We agree with the reviewers\' remark and we added relevant discussion in the revised manuscript.

> 3\) New Figure 4. It is possible that the number of MuSCs is not decreased but rather Pax7 at the level of the gene-protein is decreased. It is important to quantify MuSCs number using a different antibody (syn-4, or m-cadherin). The answer to this question would help to determine the severity of the Pax7 haplo-insufficiency phenotype. In addition, the images representing the figure need to be accompanied by quantification, for instance, the number and size of regenerating fibers across the 3 groups.

When quantified using M-cadherin, MuSCs were reduced from wt to Cre control and further from Cre control to *Cdkn1c* cKO ([Author response image 1](#respfig1){ref-type="fig"}), as originally reported in Figure 4.

![Quantification of M-cadherin+ MuSCs in regenerating muscle of wildtype littermate (Wt; *Pax7^+^;Cdkn1c^+^*), Cre control (*Pax7^CreERT2^*), and *Cdkn1c* cKO (*Pax7^CreERT2^;Cdkn1c^Flox^*) mice at D7 post-cardiotoxin injection.](elife-33337-resp-fig1){#respfig1}

The post-injury fiber size distributions were added in the revised manuscript, in Figure 4---figure supplement 1.

> 4\) New Figure 4. The observed reduced number of Pax7+ cells should also be discussed in more detail, as in most of the other assays the authors show that deletion of Cdkn1c leads to increased self-renewal and impaired myogenic differentiation. It would be useful if the authors could comment on this phenotypic difference in the different conditions. A more thorough analysis of the in vivo phenotype may resolve these contradictions.

The difference in MuSC self-renewal (*Cdkn1c* mutant) or exhaustion (*Cdkn1c* cKO) could be attributed to the constitutive versus conditional deletion of the gene, respectively, that could activate different compensatory mechanisms. The myogenic differentiation defect is consistent in both mutant and cKO mice, in our in vivo or ex vivo analyses. These clarifications have been added to the text and the phenotypes of germline and conditional KO mice are comparatively discussed in the updated manuscript.

[^1]: Tissue Regeneration Laboratory, Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.
